

## DAFTAR PUSTAKA

- Akhondi M, Sabzevari A, Imannezhad S, et al. Efficacy of methylene blue for on vasoplegic syndrome. *Rev Clin Med* 2016;3(2):69–72.
- Almashrafi A, Alsabti H, Mukaddirov M, et al. Factors associated with prolonged length of stay following cardiac surgery in a major referral hospital in Oman: A retrospective observational study. *BMJ Open* 2016;6(6):1–8.
- Blacker SN, Whalem FX. Vasoplegic Syndrome: Does the Timing of Methylene Blue Matter? *J Anesth Clin Res* 2013;4(6):6–8.
- Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery—review of pathophysiology and update of treatment options. *Crit Care* 2020;24(1):36.
- Cho JS, Song JW, Na S, et al. Effect of a single bolus of methylene blue prophylaxis on vasopressor and transfusion requirement in infective endocarditis patients undergoing cardiac surgery. *Korean J Anesthesiol* 2012;63(2):142.
- Del Duca D, Sheth SS, Clarke AE, et al. Use of Methylene Blue for Catecholamine-Refractory Vasoplegia from Protamine and Aprotinin. *Ann Thorac Surg* 2009;87(2):640–2.
- Evora PRB, Ribeiro PJ de F, Vicente WV de A, et al. Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. *Rev Bras Cir Cardiovasc* 2009;24(3):279–88.
- Faber P, Ronald A, Millar BW. Methylthioninium chloride: Pharmacology and clinical applications with special emphasis on nitric oxide mediated vasodilatory shock during cardiopulmonary bypass. *Anaesthesia* 2005;60(6):575–87.
- Furnish C, Mueller SW, Kiser TH, et al. Hydroxocobalamin Versus Methylene Blue for Vasoplegic Syndrome in Cardiothoracic Surgery: A Retrospective Cohort. *J Cardiothorac Vasc Anesth* 2020;34(7):1763–70.
- Ginimuge PR, Jyothi SD. Methylene blue: revisited. *J Anaesthesiol Clin Pharmacol* 2010;26(4):517–20.
- Habib AM, Elsherbeny AG, Almehizia RA. Methylene blue for vasoplegic syndrome postcardiac surgery. *Indian J Crit Care Med* 2018;22(3):168–73.

- Hartmann C, Radermacher P, Wepler M, et al. Non-Hemodynamic Effects of Catecholamines. *Shock* 2017;48(4):390–400.
- Hessler M, Kampmeier TG, Rehberg S. Effect of non-adrenergic vasopressors on macro- and microvascular coupling in distributive shock. *Best Pract Res Clin Anaesthesiol* 2016;30(4):465–77.
- Hosseinian L, Weiner M, Levin MA, et al. Methylene Blue: Magic Bullet for Vasoplegia? *Anesth Analg* 2016;122(1):194–201.
- Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control Clin Trials* 1996;17(1):1–12.
- Jentzer JC, Vallabhajosyula S, Khanna AK, et al. Management of Refractory Vasodilatory Shock. *Chest* 2018;154(2):416–26.
- Jiang Z, Duong T. Methylene blue treatment in experimental ischemic stroke: A mini-review. *Brain Circ* 2016;2(1):48.
- Julian H, Sally G. Cochrane handbook for systematic reviews of interventions version 5.1.0. *The Cochrane Collaboration* 2011.
- Lambden S, Creagh-Brown BC, Hunt J, et al. Definitions and pathophysiology of vasoplegic shock. *Crit Care* 2018;22(1):1–8.
- Lenglet S, MacH F, Montecucco F. Methylene blue: Potential use of an antique molecule in vasoplegic syndrome during cardiac surgery. *Expert Rev Cardiovasc Ther* 2011;9(12):1519–25.
- Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. *Ann Thorac Surg* 2004;77(2):496–9.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62:1–34.
- Liu J-J, Lu L, Hu F-Q, et al. Methylene blue attenuates renal ischemia-reperfusion injury by negative regulation of NLRP3 signaling pathway. *Eur Rev Med Pharmacol Sci* 2018;22(9):2847-2853.
- Maslow AD, Stearns G, Batula P, et al. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. *Anesth Analg* 2006;103(1):2–8.

- McCartney SL, Duce L, Ghadimi K. Intraoperative vasoplegia: Methylene blue to the rescue! *Curr Opin Anaesthesiol* 2018;31(1):43–9.
- Mekontso-Dessap A, Houël R, Soustelle C, et al. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. *Ann Thorac Surg* 2001;71(5):1428–32.
- Ortoleva J, Shapeton A, Vanneman M, et al. Vasoplegia During Cardiopulmonary Bypass: Current Literature and Rescue Therapy Options. *J Cardiothorac Vasc Anesth* 2020;34(10):2766–75.
- Özal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. *Ann Thorac Surg* 2005;79(5):1615–9.
- Porizka M, Kopecky P, Dvorakova H, et al. Methylene blue administration in patients with refractory distributive shock - a retrospective study. *Sci Rep* 2020;10(1):1828.
- Radovic M, Bojic S, Kotur-Stevuljevic J, et al. Serum lactate as reliable biomarker of acute kidney injury in low-risk cardiac surgery patients. *J Med Biochem* 2019;38(2):118–25.
- Schumacher LED, Blumer V, Chaparro S V. Methylene blue–induced serotonin syndrome after left ventricular assist device implantation: A case report and literature review. *J Thorac Cardiovasc Surg* 2017;154(3):e39–43.
- Shaefi S, Mittel A, Klick J, et al. Vasoplegia After Cardiovascular Procedures—Pathophysiology and Targeted Therapy. *J Cardiothorac Vasc Anesth* 2018;32(2):1013–22.
- Shen Q, Du F, Huang S, et al. Neuroprotective efficacy of methylene blue in ischemic stroke: An MRI study. *PLoS One* 2013;8(11):e79833.
- Soares ROS, Losada DM, Jordani MC, et al. Ischemia/reperfusion injury revisited: An overview of the latest pharmacological strategies. *Int J Mol Sci* 2019;20(20):5034.
- VanValkinburgh D, Kerndt CC, Hashmi MF. Inotropes And Vasopressors. StatPearls, <http://www.ncbi.nlm.nih.gov/pubmed/29494018> (2020, Accessed 23 October 2020).
- Vincent JL, Nielsen ND, Shapiro NI, et al. Mean arterial pressure and mortality in patients with distributive shock: a retrospective analysis of the MIMIC-III database. *Ann Intensive Care* 2018;8(1):1-10.

Vives M, Hernandez A, Parramon F, et al. Acute kidney injury after cardiac surgery: Prevalence, impact and management challenges. *Int J Nephrol Renovasc Dis* 2019;12:153–66.

Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of non-randomised studies in meta analysis. Ottawa: Ottawa Hospital Research Institute, [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) (n.d, Accessed 23 October 2020).